Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

2.6K
Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.6K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology01:20

Chronic Obstructive Pulmonary Disease-II: Pathophysiology

2.7K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
2.7K
Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

359
Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
359
Chronic Obstructive Pulmonary Disease-I: Introduction01:20

Chronic Obstructive Pulmonary Disease-I: Introduction

2.8K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
2.8K
COPD: Management Using Bronchodilators and Corticosteroids01:26

COPD: Management Using Bronchodilators and Corticosteroids

182
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
182
COPD: Pathogenesis and Clinical Features01:20

COPD: Pathogenesis and Clinical Features

235
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
235

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

COPD maintenance trials use heterogeneous outcomes and measurement instruments: a systematic literature review.

European respiratory review : an official journal of the European Respiratory Society·2026
Same author

Aim High-Stay Stable: Rethinking Treatment Success in COPD.

American journal of respiratory and critical care medicine·2026
Same author

Remission in Global Airway Diseases: EUFOREA Consensus Paper.

Allergy·2026
Same author

ERS Congress 2025: highlights from the Airway Diseases Assembly.

ERJ open research·2026
Same author

Small airways disease is common in mild COPD and symptomatic subjects at risk with normal spirometry: baseline data from CAPTO-COPD.

ERJ open research·2026
Same author

Find your career: the ERS "My Career Path" series.

Breathe (Sheffield, England)·2026

Related Experiment Video

Updated: Jun 7, 2025

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.5K

Type 2 inflammation in COPD: is it just asthma?

Augusta Beech1,2,3, Andrew Higham1,3, Sophie Booth1,2

  • 1Division of Immunology, Immunity to Infection and Respiratory Medicine, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester and Manchester University NHS Foundation Trust, Manchester, UK.

Breathe (Sheffield, England)
|November 13, 2024
PubMed
Summary

Type 2 inflammation occurs in some chronic obstructive pulmonary disease (COPD) patients, differing from asthma. Understanding these differences may explain varied treatment responses and disease phenotypes.

More Related Videos

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.6K
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

7.4K

Related Experiment Videos

Last Updated: Jun 7, 2025

Methodology for Sputum Induction and Laboratory Processing
13:28

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

27.5K
Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy
10:39

Advanced Imaging of Lung Homing Human Lymphocytes in an Experimental In Vivo Model of Allergic Inflammation Based on Light-sheet Microscopy

Published on: April 16, 2019

7.6K
An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses
08:16

An IL-8 Transiently Transgenized Mouse Model for the In Vivo Long-term Monitoring of Inflammatory Responses

Published on: July 7, 2017

7.4K

Area of Science:

  • Pulmonology
  • Immunology
  • Respiratory Medicine

Background:

  • Chronic obstructive pulmonary disease (COPD) is a heterogeneous respiratory condition primarily caused by tobacco smoking.
  • Type 2 (T2) inflammation, a known feature in asthma, is increasingly recognized in a subset of COPD patients, indicated by elevated eosinophils and altered T2 mediator expression.

Purpose of the Study:

  • To review and compare the nature of T2 inflammation in COPD versus asthma.
  • To explore how these differences may explain distinct disease phenotypes and variable responses to T2-targeted therapies.

Main Methods:

  • Narrative review of existing literature.
  • Focus on evidence from pulmonary histopathology, sputum analysis, and epithelial gene/protein expression.
  • Analysis of patient responses to pharmacological interventions targeting T2 inflammation.

Main Results:

  • T2 inflammation presents differently in COPD compared to asthma.
  • Differences in T2 inflammation characteristics may contribute to observed phenotypic variations between the two diseases.
  • Variability in therapeutic efficacy for T2-targeted drugs between COPD and asthma is noted.

Conclusions:

  • The nature of T2 inflammation is not identical in COPD and asthma, impacting disease presentation.
  • Recognizing these distinctions is crucial for understanding disease heterogeneity and optimizing therapeutic strategies in respiratory medicine.